Within the evidentiary hierarchy of experimental inquiry, randomized trials are the gold standard. Oncology patients enter clinical studies with diverse lifestyles, treatment pathways, host tissue environments, and competing comorbidities. Randomization attempts to balance prognostic characteristics among study arms, thereby enabling statistical inference of 'average benefit' and attribution to the studied therapies. In contrast, interpretations of uncontrolled trials require additional scrutiny to attempt to place the findings in the context of external evidence. Counter-factual reasoning and speculation across trials may be obscured by the disproportionate enrollment of prognostic subpopulations which may be unknown from publications of trial reports. Recent modifications to the regulatory environment (Food and Drug Administration Safety and Innovation Act) have elevated the importance of non-comparative trials. Moreover, the emergence of recent innovations in precision medicine have yielded trial designs that partition potentially heterogeneous subpopulations into 'statistically exchangeable' cohorts by histologies, or genetic alterations, further elevating the importance of single-cohort analyses. As patient cohorts become ever more refined into smaller targeted subsets, consumers of reports of uncontrolled trials should be further empowered with improvements in reporting practices that better describe the enrolled prognostic subpopulations and importantly their association with study end points. This article demonstrates the issue with a sensitivity analysis of the findings reported in a recent trial that was devised to evaluate the preliminary clinical efficacy of vemurafenib in BRAF V600 mutationpositive nonmelanoma cancers.
Introduction
Experimental studies acquire objective data to evaluate the effect of therapeutic interventions on target populations. Objective data are translated into a measure of statistical evidence through the likelihood principle, often using models that explicitly assume that the trial participants contribute statistically exchangeable information [1] . Factors independent of the interventions (method of experimental design, representativeness of the enrolled subpopulation, and extent of heterogeneity in the target population from which the enrolled subpopulation was sampled) often determine the extent to which the trial yields reproducible findings and can be combined with external evidence to evaluate treatment benefit in comparison to competing treatment strategies. Attempts to ascertain treatment benefit from data can be obscured by potential imbalances among prognostic determinants across comparison cohorts. Intrinsic to randomized design is the desire to infer causal relationships from population-average trends using random allocation strategies that attempt to balance prognostic determinants (both known and unknown), and thereby facilitate a valid statistical inference of average treatment benefit. By way of contrast, interpretations of uncontrolled (nonrandomized) trials require additional scrutiny to attempt to place the findings in the context of external evidence. Counterfactual reasoning and speculation across trials is challenging with oncology studies since trial participants are seldom statistically exchangeable, but rather exhibit a considerable extent of heterogeneity in disease prognostication which is multifaceted in its characterization and dynamic over time and treatment course.
With the aim of accelerating the development of cancer therapeutics, the Food and Drug Administration Safety and Innovation Act (FDASIA) has created a pathway for breakthrough therapy designation [2] . The pathway facilitates frequent interactions between sponsors and the FDA to expedite the development of the most promising agents for serious and lifethreatening diseases. From its initial implementation in 2012 through 15 March 2018, the breakthrough designation has been awarded to more than 77 cancer drugs for 94 indications [3] . Immunotherapies in particular have benefited from development using the breakthrough therapy designation. The result has been accelerated approvals based on non-comparative trials with analysis of single-arm cohorts. While distinctions among the various methods of experimental study have been well established and placed within evidentiary hierarchies [4] , trial reporting practices persist as design-invariant, aligning with the study objective but not the methodology. Consumers of reports of uncontrolled trials can be further empowered with improvements in trial reporting practices that better describe the enrolled prognostic subpopulations and their association with study end points.
With the adoption of innovations in trial design for precision medicine [5] [6] [7] [8] , trials designed as 'master protocols' further divide potentially heterogeneous subpopulations into 'statistically exchangeable' cohorts by specific histologies or genetic alterations. As patient cohorts become ever more refined into smaller targeted subsets, it becomes pivotal that trial reports elucidate the influences that prognostic factors have exerted on a study's conclusions. In the interest of improving the clarity of findings in the context of external evidence, the reporting of these studies should explicitly interrogate the prognostic heterogeneity of enrolled populations and their associations with study end points when implemented without randomization. To demonstrate the issue, we have conducted sensitivity analyses of the findings conveyed in a recently reported basket trial which was devised to evaluate the preliminary clinical efficacy of vemurafenib in BRAF V600 mutation-positive nonmelanoma cancers [9] .
Sensitivity analysis of the vemurafenib trial Study design and reported results
The trial enrolled patients into predetermined cohorts or 'baskets' that were determined by organ site with primary end point defined by Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 [9] or the criteria of the International Myeloma Working Group (IMWG) [10] . Statistical evidence for preliminary clinical efficacy was obtained through estimation of the organ-specific objective response rates at 8 weeks following the initiation of treatment. Our investigation focused on six organs comprising non-small-cell lung cancer (NSCLC), cholangiocarcinoma (Bile Duct), Erdheim-Chester disease or Langerhans'-cell histiocytosis (ECD/LCH), anaplastic thyroid cancer (ATC), and colorectal cancer (CRC) which formed two cohorts. Patients with CRC were initially administered vemurafenib. The study was later amended to evaluate vemurafenib in combination with cetuximab for CRC which comprised a new cohort. Table 1 provides data reported in Hyman et al. among 90 patients enrolled among the six cohorts. In total, 18 responders were observed among the 84 patients contributing evaluable outcomes for statistical estimation. Observed response rates varied from 42% and 43% for NSCLC and ECD/LCH to 0 and 4%, for CRC with vemurafenib mono and combination therapies, respectively. With two responders of seven patients, ATC was associated with a 29% response rate, while one responder of eight patients was observed in the cholangiocarcinoma cohort. Contrasting favorable results for preliminary vemurafenib activity among NSCLC and ECD/LCH patients with less favorable results for CRC patients, the authors concluded that nonmelanoma tumor types harboring BRAF V600 mutations failed to respond uniformly to BRAF targeted therapy giving credence to more conventional organ-specific nosology when compared with molecular tumor nosology.
And yet for this patient population, the distribution of the number of systemic therapies received before enrollment varied among the six cohorts. As observed in Table 1 , 55%, 50%, and 71% of the patients enrolling into the 'favorable' cohorts (NSCLC, ECD/LCH, ATC) had received at most one prior therapy, while 70%, 41%, and 62.5% of patients enrolling into unfavorable cohorts (CRC and Bile Duct) had already failed a minimum of three prior systemic treatments.
Findings discerned by the response rates alone make the implicit assumption that patients within concordant organ cohorts contribute statistically exchangeable information. Consequently, potential for differential prognostic value is not conferred by one's treatment history. Since the reader cannot rule out the presence of interdependence, which is not discernable from the data reported, we undertook a sensitivity analysis which was devised to interrogate the extent to which findings from the vemurafenib trial may be impacted by association between tumor response and prior therapy history given its observed maldistribution among the study cohorts.
Permutation study design
Our sensitivity analysis was based solely on the marginal summary statistics reported in Hyman et al., which describe the univariate distributions of counts of observed prior treatment failures (PTF) and objective responses. Evidence for a prognostic relationship between prior treatment history and tumor response is determined by their bivariate distribution, which was not described in the trial report. Through evaluations of possible pairings of these variables, our permutation study was designed to explore the robustness of the study's conclusions in the presence of a plausible extent of prognostic effect attributable to PTF.
Prior treatment failures were reported for all 90 enrolled patients, while only 84 were evaluable for tumor response. Let n j denote the number of assessable patients observed within cohort j and let Y ji denote the presence (Y ¼ 1) or absence (Y ¼ 0) of tumor response for the ith patient observed in cohort j. Permutations matching each reported objective response with a reported number of prior treatment failures were generated by the following process.
For each cohort j, a random sample of n j reported PTFs was drawn from the distribution of PTF counts reported for patients enrolled in cohort j. Thereafter, each sampled PTF count was randomly matched to an observed response. Considering one realization of this permutation, let X ji denote the number of prior therapies (either 0, 1, 2, 3) previously administered to the ith patient observed in cohort j matched to response Y ji . The process was repeated to produce 30 000 random permutations of the data reported in Hyman et al., which collectively span the domain of plausible associations between PTF and tumor response, while maintaining the observed marginal distributions of each variable.
To evaluate the extent to which the statistical evidence for preliminary efficacy may be impacted by the presence of dependence with PTF, Bayesian analysis of each permuted dataset was implemented. The Hyman et al.'s study was formulated to apply the adaptive Simon two-stage design [11] to each cohort, individually. The investigators conveyed cohort-invariant success criteria, such that for any cohort j a true response probability, p j , of 0.15 would be inadequately low. Thus, we've devised the sensitivity analysis to measure the extent of statistical evidence through the posterior probability that p j exceeds 0.15 based on the observed data: p j ð Þ ¼ Pr p j > 0:15 ð jDataÞ. Column 2 of Table 2 reports this posterior probability for each of the six cohorts based solely on the observed response data reported by Hyman et al. under the a priori assumption that each p j follows the conventional weakly informative Beta(0.5, 0.5) distribution. A two-sided symmetric Bayesian test based on this posterior probability controls type I error at 0.1 for a significance threshold of p > 0:971, which based on the response data alone would confer statistical significance for the preliminary clinical efficacy of NSCLC and ECD/LCH. Now considering the potential for confounding arising from association with prior treatment history, our permutation study evaluated adjusted posterior probabilities that take into account the potential for the independent prognostic effect of PTF. Assuming that tumor response for patient i of cohort j occurs with probability p ji , the independent contributions of cohort and PTF were characterized by the following logistic model
Parameter expðkÞ denotes an odds ratio (OR) characterizing the extent of independent association with PTF such that values >1 represent increasing per unit fold-reductions in the odds of achieving a tumor response. The OR is assumed to be common for all organ cohorts. This assumption is consistent with the Hyman et al. study design strategy, which explicitly assumed a common null response rate for all organ sites. Parameter l j characterizes the independent contribution of treatment of cohort j. The adjusted response probability for cohort j derives from this model as p j ¼ f1 þ exp Àl j ð Þ g À1 . Analysis assumed independent, noninformative Gaussian prior distributions for each l j [12] . The prior distribution for expðkÞ assumed a non-informative gamma with median fixed at 1, reflecting the condition of a priori vaguity and impartiality about the prognostic value of knowing one's prior treatment history. All statistical calculations were implemented in R version 2.12.2 [13] with permutations generated using the samples function. Implementation of Bayesian analysis used OpenBUGS software version 3.2.2 [14] through the BRugs R library [15] .
Permutation study results Figure 1 provides scatterplots of the resulting adjusted posterior probabilities as functions of the estimated magnitude of prognostic effect that was attributable to PTF. Specifically, each point in each scatterplot corresponds to a single permutation of the Hyman et al. data plotted at the estimated posterior probability that p j exceeded 0.15 from model (1) (y-axis) and estimated posterior median odds ratio attributable to prior therapy (x-axis). Red horizontal lines depict unadjusted posterior probabilities estimated from the response data alone and thus intersect with the adjusted measures at OR ¼ 1. Column 3 of Table 2 reports the proportion of permutations that yielded an adjusted posterior probability that was larger than the unadjusted estimate based on the response rate alone. Summary statistics of the distributions of adjusted posterior probabilities are provided in columns 4 and 5.
Here, we have several findings. In the presence of any extent of negative association between tumor response and prior therapy (OR > 1), robustness was evident for the most favorable cohorts of NSCLC and ECD/LCH. These cohorts obtained median adjusted posterior probabilities of 0.998 and 0.995, respectively. Moreover, for both cohorts, the minimums of adjusted posterior probabilities attained in the permutation study (reflecting the minimal extent of evidence for preliminary clinical efficacy) exceeded the significance threshold of 0.971. A high degree of prognostic effect for prior therapy (OR > 2) yielded more favorable measures of evidence for these cohorts, as well as for ATC which attained a median adjusted posterior probability of 0.945 in this scenario. When considering possible arrangements of PTF and response that could have been observed in the trial, roughly 96% of all permutations yielded adjusted posterior probabilities that were larger than their unadjusted estimates for the CRC cohorts. Moreover, with adjusted posterior probabilities ranging (0.111-0.499) and (0.074-0.713) for mono and combination therapies, respectively, CRC cohorts exhibited high uncertainty for estimation of the independent attribution to therapy. While Hyman et al. noted that patients in both colorectal cancer cohorts were 'heavily pre-treated', definitive conclusions were avoided. The authors do convey that strategies using dual epidermal growth factor receptor and BRAF inhibition deserve further evaluation. Yet, the extent of association between pretreatment and tumor response was not provided in the article. Other authors [9, [16] [17] [18] [19] have conveyed an absence of effect of vemurafenib in colon tumors. On the basis of our evaluation, however, with only 16% of CRC patients having experienced one or no prior therapy, the vemurafenib trial may have had little statistical power to detect an indication for preliminary efficacy in patients for the first-or second-line therapy. Conclusions for this subset should perhaps be avoided on the basis of this study. More clarity could have been conveyed given improved reporting standards. Figure 1 . Scatterplots of the resulting adjusted posterior probabilities from our permutation study. Each point corresponds to a single permutation of the Hyman et al. [9] data plotted at the estimated posterior probability that p j exceeded 0.15 obtained from model (1) (y-axis) and estimated posterior median odds ratio attributable to prior therapy number (x-axis). Red horizontal lines depict unadjusted posterior probabilities estimated from the response data alone.
Discussion
Despite being widely accepted as achieving a lower rank in the evidentiary hierarchy, the uncontrolled study plays a pivotal role in clinical oncology. Its influence has been further elevated with the recent creation of a regulatory pathway for breakthrough therapy designation through FDASIA. Interpretations of findings from uncontrolled trials, however, may become detached from the method of design in their dissemination. As uncontrolled trials require additional scrutiny, their reporting should explicitly encourage the examination of the influence that prognostic determinants have exerted on the resultant conclusions. This is especially critical in oncology settings with designs for precision medicine, whereby characterization of a patient's histology and/ or a mutation status alone may be insufficient to ensure an exchangeable patient cohort.
Our sensitivity analysis was intended to elucidate the potential for conclusions of master protocols to be influenced by maldistributed prognostic factors in the absence of randomization. This required the assumption that patients with differing prior treatment histories may have enrolled into the trial with differing a priori expectations of obtaining a tumor response. This assumption, if accurate, would have violated the reported evidentiary measures, which explicitly assume that patients enroll into the trial as exchangeable units. We are not aware, however, if this assumption is indeed true for the specific targeted therapy and studied population. Furthermore, evidence to evaluate the assumption was not included in the trial report.
One should note that authors have considered strategies for developing targeted agents with trial designs devised to evaluate multiple tumor indications in the confirmatory setting [20] . These designs may include randomized comparisons as well as sequential 'pruning' of ineffective tumor subtypes. Our investigation suggests that decision-rules for sequential statistical evaluations of specific tumor indications may be limited when formulated on the basis of response rates alone.
Our permutation study did not simulate any data, but rather considered possible pairings between counts of objective responses and prior treatment failures conveyed in the trial report. Adjusted posterior probabilities were computed in accordance with the trial's reported design strategy, for which hypothesis testing assumed identical null response rates for all organ sites. This assumption, if violated, would preclude implementation of basket trials devised to pool patients harboring common molecular tumor types arising from disparate clinical subtypes. Recent adaptive Bayesian design methodology has been established to monitor heterogeneity among tumors with common genetic alteration [21] .
It is additionally important to note that our sensitivity analysis considered the potential impact of only one maldistributed prognostic factor. Several imbalances could exist, however, when comparing response rates from any two disparate uncontrolled trials with limited sample size. Consumers of future reports of uncontrolled trials stand to benefit from reporting practices that further enhance clarity as it pertains to the robustness of trial conclusions in relation to enrolled study populations. Requiring the reporting of statistical associations between study end points and the characteristics of the enrolled study population (often presented in Table 1 ) would represent a simple first step.
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